These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27063977)

  • 1. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
    Berthon C; Raffoux E; Thomas X; Vey N; Gomez-Roca C; Yee K; Taussig DC; Rezai K; Roumier C; Herait P; Kahatt C; Quesnel B; Michallet M; Recher C; Lokiec F; Preudhomme C; Dombret H
    Lancet Haematol; 2016 Apr; 3(4):e186-95. PubMed ID: 27063977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
    Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
    Odore E; Lokiec F; Cvitkovic E; Bekradda M; Herait P; Bourdel F; Kahatt C; Raffoux E; Stathis A; Thieblemont C; Quesnel B; Cunningham D; Riveiro ME; Rezaï K
    Clin Pharmacokinet; 2016 Mar; 55(3):397-405. PubMed ID: 26341814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
    Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
    Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
    Martinelli G; Oehler VG; Papayannidis C; Courtney R; Shaik MN; Zhang X; O'Connell A; McLachlan KR; Zheng X; Radich J; Baccarani M; Kantarjian HM; Levin WJ; Cortes JE; Jamieson C
    Lancet Haematol; 2015 Aug; 2(8):e339-46. PubMed ID: 26688487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
    Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
    Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
    Lewin J; Soria JC; Stathis A; Delord JP; Peters S; Awada A; Aftimos PG; Bekradda M; Rezai K; Zeng Z; Hussain A; Perez S; Siu LL; Massard C
    J Clin Oncol; 2018 Oct; 36(30):3007-3014. PubMed ID: 29733771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
    Daver NG; Montesinos P; DeAngelo DJ; Wang ES; Papadantonakis N; Todisco E; Sweet KL; Pemmaraju N; Lane AA; Torres-Miñana L; Thompson JE; Konopleva MY; Sloss CM; Watkins K; Bedse G; Du Y; Malcolm KE; Zweidler-McKay PA; Kantarjian HM
    Lancet Oncol; 2024 Mar; 25(3):388-399. PubMed ID: 38423051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
    Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
    Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
    Salamero O; Molero A; Pérez-Simón JA; Arnan M; Coll R; Garcia-Avila S; Acuña-Cruz E; Cano I; Somervaille TCP; Gutierrez S; Arévalo MI; Xaus J; Buesa C; Limón A; Faller DV; Bosch F; Montesinos P
    Lancet Haematol; 2024 Jul; 11(7):e487-e498. PubMed ID: 38824932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
    Sallman DA; Kerre T; Havelange V; Poiré X; Lewalle P; Wang ES; Brayer JB; Davila ML; Moors I; Machiels JP; Awada A; Alcantar-Orozco EM; Borissova R; Braun N; Dheur MS; Gilham DE; Lonez C; Lehmann FF; Flament A
    Lancet Haematol; 2023 Mar; 10(3):e191-e202. PubMed ID: 36764323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
    Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
    Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.